Cargando…

2. Two cases of anti-MDA5 positive dermatomyositis with rapidly progressive interstitial lung disease

INTRODUCTION: Melanoma differentiation-associated gene 5 (MDA5) is a myositis-associated autoantibody. It is increasingly being recognised that this antibody presents with typical skin lesions and the potential for a rapidly progressive interstitial lung disease but without muscle involvement. We pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levasseur, Kirsty, Tosounidou, Sofia, Rajasekaran, Arvind, Lim, Zhia, McGrath, Catherine, Chandratre, Priyanka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Oral Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761396/ http://dx.doi.org/10.1093/rap/rkz026.001

Ejemplares similares

18. Hot off the Presses - Applying the 2017 British Society for Rheumatology Guidelines in a Patient with Polyarticular Tophaceous Gout and Renal Impairment
por: McGrath, Catherine, et al.
Publicado: (2017)

OA16 A case of anti-MDA5 dermatomyositis: the challenge of atypical skin manifestations
por: Biddle, Kathryn, et al.
Publicado: (2023)

8. Myositis as an idiosyncratic drug reaction to leflunomide
por: Darren, Angeline, et al.
Publicado: (2019)

Roles of biomarkers in anti‐MDA5‐positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease
por: Li, Xiaomeng, et al.
Publicado: (2022)

Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases
por: Mehta, Asmita A, et al.
Publicado: (2021)

Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: The CRAFT Model
por: Guo, Jinqiang, et al.
Publicado: (2023)

OA05 Clinical presentation, risk factors and prognosis of MDA5-positive JDM; clinical diversity and red flags
por: McLellan, Kirsty, et al.
Publicado: (2022)

50. Vascular BehÇet’s disease in a 20-year-old man presenting with an abdominal aortic aneurysm
por: Levasseur, Kirsty, et al.
Publicado: (2019)

9. Successful use of IL-6 pathway blockade to treat autoinflammation occurring in the context of a novel TNFRS1A gene mutation
por: Dyke, Bernard, et al.
Publicado: (2019)

7. Anti-MDA5 associated dermatomyositis
por: Laverty, Ursula, et al.
Publicado: (2019)

Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis
por: Sakamoto, Noriho, et al.
Publicado: (2018)

Anti-MDA5 Associated Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Lung Disease
por: Tavakolian, Kameron, et al.
Publicado: (2022)

Management of MDA-5 antibody-positive dermatomyositis with interstitial lung disease—an Auckland case series
por: Dick, Michael, et al.
Publicado: (2021)

Editorial: Anti-MDA5-Positive Dermatomyositis
por: Gono, Takahisa, et al.
Publicado: (2022)

4. A paraneoplastic case of dermatomyositis
por: Wilson-Morkeh, Harold, et al.
Publicado: (2019)

Sub-phenotyping of juvenile dermatomyositis: can it assist clinical decisions?
por: Yasin, Shireena A, et al.
Publicado: (2014)

Acral Cutaneous Ulcerations and Livedo Reticularis with Rapidly Progressive Interstitial Lung Disease in Anti-MDA5 Antibody-Positive Classical Dermatomyositis
por: Wongjirattikarn, Rachot, et al.
Publicado: (2020)

Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome
por: Zuo, Yu, et al.
Publicado: (2022)

Anti-MDA5 Antibody-positive Dermatomyositis with Rapidly Progressive Interstitial Pneumonia Presenting with Nephrotic Syndrome during Treatment with Corticosteroids and Cyclosporine
por: Kawamoto, Shinya, et al.
Publicado: (2021)

Toll-like receptor 2 polymorphism in juvenile dermatomyositis
por: Mathiesen, P, et al.
Publicado: (2011)

Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report
por: Endo, Yushiro, et al.
Publicado: (2018)

Double anti-PL-7 and anti-MDA-5 positive Amyopathic Dermatomyositis with rapidly progressive interstitial lung disease in a Hispanic patient
por: Li, Zi Ying, et al.
Publicado: (2020)

Anti-MDA5 Positive Dermatomyositis Associated with Rapidly Progressive Interstitial Lung Disease and Correlation between Serum Ferritin Level and Treatment Response
por: Zohar, Daniela Noa, et al.
Publicado: (2020)

10. Is Eculizumab a life-saving treatment for atypical Haemolytic Uraemic Syndrome in Lupus Pregnancy?
por: McGrath, Catherine, et al.
Publicado: (2017)

Successful Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis-Associated Rapidly Progressive-Interstitial Lung Disease by Plasma Exchange: Two Case Reports
por: Takahashi, Rina, et al.
Publicado: (2021)

Plasma exchange for anti-MDA5 antibody-positive dermatomyositis-associated rapidly progressive interstitial lung disease: A case report and literature review
por: Lu, Ci, et al.
Publicado: (2023)

Effectiveness of anti-TNF-α agents in the treatment of refractory juvenile dermatomyositis
por: Boulter, EL, et al.
Publicado: (2011)

Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease
por: Li, Liubing, et al.
Publicado: (2017)

Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis Complicated by Unilateral Right-sided Interstitial Lung Disease
por: Kori, Mayuko, et al.
Publicado: (2020)

Aberrantly Expressed Galectin-9 Is Involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease
por: Liang, Lin, et al.
Publicado: (2021)

A Computed Tomography Radiomics-Based Prediction Model on Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis
por: Xu, Wenwen, et al.
Publicado: (2021)

Clinically amyopathic dermatomyositis with interstitial lung disease double-positive for anti-MDA5 and anti-PL12 antibodies
por: Hiramatsu, Toshiya, et al.
Publicado: (2022)

Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis
por: Li, Yuhui, et al.
Publicado: (2020)

A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis
por: Xu, Wenwen, et al.
Publicado: (2021)

Anti-MDA5 Antibody-Positive Interstitial Pneumonia with Autoimmune Features Presenting as Amyopathic Hypodermatitic Dermatomyositis: A Case Report
por: Mihailescu, Maria L., et al.
Publicado: (2021)

13. Progress of Pregnancies in a Patient with Previously Treated Thrombotic Thrombocytopaenic Purpura and Lupus
por: McGrath, Catherine, et al.
Publicado: (2017)

Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody
por: Wang, Huyan, et al.
Publicado: (2023)

Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib
por: Luo, Man, et al.
Publicado: (2022)

Clinical Features of Dermatomyositis/Polymyositis with Anti-MDA5 Antibody Positivity
por: Chen, Qiuhe, et al.
Publicado: (2022)

Subcutaneous Calcinosis in a Patient with Anti-MDA5 Positive Dermatomyositis
por: Hou, Ruihong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2hdmjn9cac2es21kgnfile0clr